The anti-HIV activity of ADS-J1 targets the HIV-1 gp120  by Armand-Ugón, Mercedes et al.
www.elsevier.com/locate/yviroVirology 343 (20The anti-HIV activity of ADS-J1 targets the HIV-1 gp120
Mercedes Armand-Ugo´na, Imma Clotet-Codinaa, Cristina Tintorib, Fabrizio Manettib,
Bonaventura Cloteta, Maurizio Bottab, Jose´ A. Este´a,*
aRetrovirology Laboratory IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Auto´noma de Barcelona, 08916 Barcelona, Spain
bDipartimento Farmaco Chimico Tecnologico, Universita` degli Studi di Siena, I-53100 Siena, Italy
Received 1 July 2005; returned to author for revision 29 July 2005; accepted 9 August 2005
Available online 15 September 2005Abstract
Recent data suggest that heparin sulfates may bind to a CD4 induced epitope in the HIV-1 gp120 that constitutes the coreceptor binding
site. We have studied the mechanism of action of ADS-J1, a non-peptidic compound selected by docking analysis to interact with gp41 and to
interfere with the formation of N-36/C-34 complexes in sandwich ELISA experiments. We show that ADS-J1 blocked the binding of wild-
type HIV-1 NL4-3 strain to MT-4 cells but not virus–cell binding of a polyanion-resistant virus. However, ADS-J1 blocked the replication of
polyanion-resistant, T-20- and C34-resistant HIV-1, suggesting a second mechanism of action.
Development of resistance to ADS-J1 on the polyanion-resistant HIV-1 led to mutations in gp120 coreceptor binding site and not in gp41.
Time of addition experiments confirmed that ADS-J1, but not polyanions such as dextran sulfate or AR177, worked at a step that mimics the
activity of an HIV coreceptor antagonist but prior to gp41-dependent fusion. We conclude that ADS-J1 may bind to the HIV coreceptor
binding site as its mechanism of anti-HIV activity.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; gp120; gp41; Fusion; Entry; Drug resistanceIntroduction
The HIV-1 envelope glycoprotein consists of two
subunits, the gp120 (superficial subunit) and gp41 (trans-
membrane subunit), that are covalently associated as triple
heterodimers (Kowalski et al., 1987; Wyatt and Sodroski,
1998). Attachment to negatively charged molecules on the
cell surface is a previous step to interaction of the envelope
glycoprotein with the CD4 cellular receptor, which renders
conformational changes in the gp120 that allow for the
interaction of gp120 with the HIV-1 coreceptor (CCR5 or
CXCR4). The amino acid sequence of gp120 and in
particular the number and position of basic residues in the
V3 loop of gp120 determine HIV coreceptor use (reviewed0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: jaeste@irsicaixa.es (J.A. Este´).in Menendez-Arias and Este, 2004). CCR5-using (R5) or
dual tropic (R5X4) (Berger et al., 1998) strains of HIV-1,
have a lower net charge of the V3 amino acid sequence than
CXCR4-using (X4) strains. Furthermore, N-linked glyco-
sylation sites of the V1/V2 and V3 loops may also affect
HIV coreceptor use (Pollakis et al., 2001).
Polyanions such as dextran sulfate (DS) and heparin
sulfate (HS) have been shown to block HIV-1 replication
through their capacity to block the attachment (binding) of
free virions to CD4+ cells. However, recent evidence
suggests that HS may bind to the HIV coreceptor binding
site of gp120 and block virus–coreceptor interactions. Thus,
some polyanions may have a secondary mode of action at a
later stage of virus–cell attachment (Vives et al., 2005).
ADS-J1 is a non-peptidic compound selected by compu-
tational docking analysis to interact with the hydrophobic
cavities on the gp41 central coiled coil. ADS-J1 has been
shown to inhibit the complex formation of gp41 N and C
peptides in an enzyme-linked immunosorbent assay
(ELISA) (Debnath et al., 1999). This approach has also05) 141 – 149
Table 1
Anti-HIV-1 activity of several compounds tested against wild-type and NL4-3 viruses resistant to peptide gp41 inhibitors (C34-res) and gp120 inhibitors
(AR177-res)
Compound EC50
a (Ag/ml) [fold-resistance]b CC50c (Ag/ml)
NL4-3 HIV-1 Wild-type NL4-3 HIV-1 C34-res NL4-3 HIV-1 AR177-res
ADS-J1 0.6 0.3 [0.5] 1.5 [2.5] >50
C34 0.0075 0.8 [107] 0.0084 >10
T-20 0.017 >5 [>294] 0.012 >5
AR177 0.65 0.72 >50 [>77] >50
DS 0.25 2.2 31.9 [>128] >50
AZT 0.003 0.004 0.002 >2
Values are mean two independent assays done in triplicate.
a EC50: effective concentration 50 or needed concentration to inhibit 50% HIV-induced cell death, evaluated with the MTT method in MT-4 cells.
b Fold resistance: mean EC50 drug-resistant virus/mean EC50 wild-type HIV-1 virus.
c CC50: cytotoxic concentration 50 or needed concentration to induce 50% death of non-infected cells, evaluated with the MTT method in MT-4 cells.
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compounds targeting gp41 (Jiang et al., 2004). However,
ADS-J1 is a polyanionic compound, and, as such, it would
be expected to interact with gp120 and block HIV binding
to cells (Este, 2003). If an underlying mechanism of action
(e.g. interaction with gp41 or coreceptor–gp120) is at work,
it could remain overlooked by the compound’s effect on
virus–cell binding.
Development of virus drug resistance is an essential
approach to elucidate the exact mechanism of action of
active anti-HIV inhibitors (Menendez-Arias and Este, 2004).
Specific mutations emerge in the amino acid coding
sequence of gp41 of HIV-1 after selective pressure with
the fusion inhibitors T-20 or C34 (Armand-Ugon et al.,
2003a) that suggest a direct interaction of these anti-HIV
agents with gp41. Here, we have analyzed the molecular
target of ADS-J1 through the development of drug-resistant
variants in cell culture. We have bypassed the inhibitory
effect of ADS-J1 on virus binding by generating drug
resistance on an HIV-1 isolate that had been previously
made resistant to the anti-HIV activity of polyanions
(Bobardt et al., 2004; Este et al., 1998; Menendez-Arias
and Este, 2004) but remained sensitive to ADS-J1. We show
that resistance to ADS-J1 was not developed through
mutations in gp41. Conversely, phenotypic resistance to
ADS-J1 was followed by the detection of amino acid
changes in the gp120 coding sequence. The positive net
charge of the V3 loop was reduced form +9 to +5 as a result
of the new residues that emerged. Time of addition
experiments suggested that a later step in virus–cell
interaction corresponding to that of gp120 interaction with
the coreceptor could account for the activity of ADS-J1.Fig. 1. Binding assay of NL4-3 wild-type (white bars) and NL4-3/AR177-
resistant strain (black bars) to lymphoid MT-4 cells. Bound viral particles
were measured by evaluating the p24 antigen bound to cell lysates. Graphic
data are mean of two similar experiments. (C) represents mock-infected
MT-4 cells. (C+) represents p24 antigen bound in the absence of drug
treatment.Results
Anti-HIV activity of ADS-J1 against drug-resistant HIV-1
Our first approach was the evaluation of the anti-HIV
activity of ADS-J1 against wild-type, C34/T-20-resistant
and polyanion-resistant HIV-1 strains. As shown in Table 1,ADS-J1 was active at 50% effective concentrations (EC50)
of 0.60 Ag/ml against the HIV-1 NL4-3 wild-type strain
(NL4-3/wt). ADS-J1 was also active against the C34-
resistant HIV-1 strain (Armand-Ugon et al., 2003a) that is
cross-resistant to T-20 (EC50 0.3 Ag/ml) and the polyanion-
resistant NL4-3/Ar177-resistant strain albeit a 2.5-fold
increase in the concentration required to block the wild-
type HIV strain cytopathic effect (EC50 1.5 Ag/ml). The
reverse transcriptase inhibitor AZT was equally active
against all strains tested. Thus, these results suggested that
mutations conferring phenotypic resistance to gp41-depend-
ent fusion inhibitors did not alter the sensitivity to ADS-J1
and that viral resistance to known polyanionic anti-HIV
agents did not markedly alter virus sensitivity to ADS-J1.
ADS-J1 blocked virus–cell binding
When we performed virus–cell binding experiments
(Fig. 1), both AR177 and ADS-J1 at 50 Ag/ml effectively
blocked the binding of wild-type HIV-1 particles to
lymphoid cells as measured by p24 antigen detection.
Compared to the untreated control, ADS-J1 reduced the
binding of wild-type virus by 20-fold. Conversely, the
Fig. 2. Time course of the development of HIV-1 resistance to ADS-J1.
HIV-1 strains were cultured in the presence of ADS-J1. Compound
concentration was increased every time detectable virus breakthrough was
noted by evaluation of the cytopathic effect in MT-4 cells.
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1.4-fold by ADS-J1 or AR177 comparable to the effect of
the retrotranscriptase inhibitor AZT (1 Ag/ml) on the
binding of NL4-3/wt or NL4-3/AR177-resistant strain
(1.5- and 1.4-fold reduction respectively).
Development of resistance to ADS-J1 and C34 on the
NL4-3/Ar177-resistant strain
Taken together, the results shown above suggest that
ADS-J1 has a mechanism of anti-HIV activity that remained
functional against both wild-type and AR177-resistant virus
despite of the observation that ADS-J1 did not prevent
AR177-resistant virus binding to lymphoid cells. Thus, our
results prompted us to start the development of resistance to
ADS-J1 on the AR177-resistant strain to bypass the
inhibition of virus binding to cells.Table 2
Anti-HIV-1 activity of compounds against virus strains that have been passaged
Compound EC50
a (Ag/ml) [fold resistance]b
HIV-1 NL4-3 HIV-1 NL4-3 AR177-res
Wild-type Parental
AR177-res
C34-res ARAwt45B2 ARA45B
ADS-J1 0.7 3.2 2.8 3.4 14.5 [4.5
AR177 0.5 >100 6.7 68.6 >100 [1
C34 0.009 0.004 5 [1250] 0.009 0.03 [8]
AZT 0.002 0.003 0.002 0.003 0.003 [1
SQV 0.009 0.008 0.006 0.007 0.020 [2
DS 0.3 78.5 1.5 1.6 120.8 [1
Values are mean of two independent assays done in triplicate.
a EC50: effective concentration 50 or needed concentration to inhibit 50% HIV-
b Fold resistance: relative loss of activity of the corresponding virus relative to t
strain/mean EC50 of the Parental AR177-resistant strain.
c CC50: cytotoxic concentration 50 or needed concentration to induce 50% dea
Values are mean of two independent assays done in triplicate.Four MT-4-infected cultures with ADS-J1 at 0.5-, 1-, 2.5-
and 5-fold the EC50 for the AR177-resistant virus and two
more without drug were started and sustained by continuous
passages. ADS-J1 concentration was maintained or
increased in the cultures with ADS-J1 until the concen-
tration of the compound reached 20 Ag/ml. Passages were
stopped after 230–270 days (Fig. 2). As result from
passaging the viruses with or without ADS-J1, we obtained
cell culture supernatant from two strains consisting of HIV-1
AR177-resistant virus grown in the absence of ADS-J1
(ARAwt45B2 and ARAwt49) and four strains derived from
AR177-resistant HIV-1 grown in presence of ADS-J1
(ARA45B2, ARA46B, ARA49 and ARA45C) (Fig. 2).
We also developed resistance to the gp41 peptide inhibitor
C34 in the AR177-resistant HIV-1 context as previously
described (Armand-Ugon et al., 2003a). Passages with C34
were stopped at 203 days in culture. Viral stocks from the
virus of the last passages were grown. Stocks were titered,
and anti-HIV activity of test compounds was re-evaluated.
Results are shown in Table 2. Comparison of the EC50 of the
different viruses showed reduced sensitivity to ADS-J1 of
the virus stocks obtained after selective pressure with ADS-
J1. Culture of cells infected with the AR177-resistant strain
in the presence of ADS-J1 rendered virus that were up to 9-
fold less sensitive to the compound than the parental
AR177-strain, retained phenotypic resistance to AR177
and DS and maintained their sensitivity to the reverse
transcriptase inhibitor AZT and the protease inhibitor SQV.
The virus strain ARA45B2 showed a reduced sensitivity (8-
fold) to the gp41 inhibitor C34, while other strains were not
modified (less than 3-fold change) by passage in the
presence of ADS-J1.
Virus passaged in the absence of ADS-J1 (ARAwt45B2
and ARAwt49) remained sensitive to ADS-J1 and resistant
to AR177 as the parental AR177-resistant strain. However,
cross-resistance to DS was reduced (49-fold and 36-fold for
ARAwt45B2 and ARAwt49 respectively). Passage of the
AR177-resistant HIV in the presence of C34 induced ain the presence of ADS-J1 or C34
CC50
c (Ag/ml)
2 ARA46B ARAwt49 ARA45C ARA49
] 30.1 [9] 4.5 23.9 [7] 26.7 [8] >50
] >100 [1] >100 >100 [1] >100 [1] >100
0.011 [3] 0.014 0.007 [2] 0.014 [3.5] >5
] 0.007 [2] 0.005 0.003 [1] 0.004 [1] >1
.5] 0.011 [1] 0.008 0.014 [2] 0.020 [2.5] >0.3
.5] 125.0 [1.5] 2.2 79.3 [1] 111.6 [1] >125
induced cell death, evaluated with the MTT method in MT-4 cells.
he Parental AR177-resistant strain calculated as the mean EC50 of the virus
th of non-infected cells, evaluated with the MTT method in MT-4 cells.
ig. 3. (A) gp120 and (B) gp41 sequences from the NL4-3/AR177 viruses. Numbering in gp120 and gp41 corresponding to the start coding sequence of each
rotein in the HXB2 HIV-1 strain. NL4-3/wt is the NL4-3 strain from which AR177 resistance was developed. ARA45B2, ARA46B, ARA45C and ARA49 are
e NL4-3/AR177-resistant viruses passed with ADS-J1. ARAwt45B2 or ARAwt49 are the viral strains obtained after passages in parallel to ARA45B2 and
RA46B or ARA45C and ARA49, respectively, but without any selective pressure. Variable loops of the gp120 are indicated by boxes.
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Fig. 4. Effect of time of drug addition on the inhibition profiles of HIVentry
inhibitors. MT-4 cells infected with HIV-1NL4-3 at an MOI of 0.5 at 20 -C
for 1 h and 37 -C thereafter were treated during virus infection and/or at
various times postinfection. Treatment with test compounds was performed
at replication-blocking concentrations. Viral p24 levels in the culturemedium
were monitored at 30 h postinfection. The results are average of two
experiments and are represented relative to its untreated control. (0) Dextran
sulfate (100 Ag/ml), (n) AR177 (50 Ag/ml), (r) ADS-J1 (50 Ag/ml), (>)
AMD3100 (1 Ag/ml), (o) T-20 (5 Ag/ml), (.) C34 (1 Ag/ml).
M. Armand-Ugo´n et al. / Virology 343 (2005) 141–149 145change in resistance to C34 (1250-fold) and loss of
resistance to AR177, while sensitivity to ADS-J1, AZT
and SQV was not modified.
DNA sequence analysis of viruses resistant to ADS-J1
shows a panel of mutations preferentially located in gp120
DNA sequences of the gp120 and gp41 were analyzed
for all viral strains, and results are summarized in Fig. 3.
The majority of mutations originally present in the parental
NL4-3/AR177 remained in ARAwt45B2 and ARAwt49
strains that were passaged in the absence of any selective
pressure. The mutations that remained were K178E (in V2),
Q310H, (in V3) F423I (in the CD4 binding domain of the
gp120 molecule) and the FNSTW deletion in V4 (Este et al.,
1998). However, the mutation K322Q that is found in the
V3 loop of the AR177-resistant strain reverted to Lysine (K)
in the absence of selective pressure. In the presence of ADS-
J1, the K322Q mutation became K322E, a drastic change
with a net loss of 2 positive charges. As shown in Fig. 3A,
the majority of additional mutations that emerged as
consequence of ADS-J1 selection were located in the
gp120 and, more specifically, in the V3 loop coding region
(K322E, N325D and R327T). Downstream from V5, a
K490R mutation was also selected in all four viruses that
were grown in the presence of ADS-J1.
Fig. 3B shows the gp41 amino acid sequence of all viral
strains after selection with ADS-J1. No mutations in
residues related to the hydrophobic cavity of gp41 were
detected including the K63 residue, thought to interact with
ADS-J1 (Jiang and Debnath, 2000). The mutation at
position Q64E was already present in the parental AR177-
resistant strain and was conserved through all passages. The
L33S mutation present in the ARA45B2 and ARA49 has
been previously shown to confer resistance to C34
(Armand-Ugon et al., 2003a; Fikkert et al., 2002). However,
selection of phenotypic resistance to C34 in the AR177-
resistant background was associated with the emergence of
the V38E mutation that has also been associated to C34
resistance (Armand-Ugon et al., 2003a).
V3 positive net charge is significantly reduced after
passages in the presence of ADS-J1
The net positive charge of the V3 loop of the ADS-J1-
resistant viruses was calculated with the GeneWorks 2.5.1
software. As consequence of mutations that appear in V3,
the net positive charge decreased from +9 to +5 in all four
ADS-J1-resistant viruses. Basic V3 loops have been
associated to preferential gain in CXCR4 use by HIV-1
(Hoffman et al., 2002; Notredame et al., 2000). As MT-4
cells do not express the CCR5 coreceptor, we further
passaged ARAwt45B2, ARA45B2 and ARA46B in both the
MT-4 cell line and the CEM-CCR5 (CCR5+ and CXCR4+)
cell line during 54 more days in the absence or presence of
20 Ag/ml of ADS-J1. After these additional passages wetested if the acidification of the V3 loop could entail an
alteration of the affinity for coreceptors CXCR4 or CCR5 in
U87-CD4 cells as previously reported (Este et al., 1999). No
change in coreceptor use was noted for any of the strains
evaluated (data not shown).
Time of drug addition studies
To identify the time/site of interaction of ADS-J1, drugs
acting at different steps of virus entry were added at various
times postinfection. The time delay before the addition of a
drug is an estimate of its mode of action. DS or AR177
required to be added at the time of infection in order to
inhibit viral production, addition of the CXCR4 antagonist
AMD3100 could be delayed for several minutes, while T-20
and C34 could be added at a later time (Fig. 4). AZT
remains completely active when added up to 3 h post-
infection (data not shown, Ojwang et al., 1995b). Addition
of ADS-J1 could be postponed in a fashion similar to
AMD3100 and clearly later than other polyanions such as
DS or AR177 but earlier than gp41 inhibitors T-20 or C34.
When added after 28 min of incubation at 37 -C, both DS
and AR177 had completely lost their inhibitory activity.
Conversely, both ADS-J1 and AMD3100 retained up to
40% of their inhibitory activity. These results suggest that
ADS-J1 may interfere with gp120–coreceptor interactions.
However, ADS-J1 did not block the binding of a mono-
clonal antibody (12G5) targeting CXCR4 or the Ca2+ flux
induced by CXCL12 (SDF-1) in CXCR4 cells (data not
shown), indicating that ADS-J1 did not interact with the
CXCR4 coreceptor.
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The identification of small molecular weight inhibitors of
gp41-dependent fusion has become apparent with the need
to circumvent disadvantages of peptidic fusion inhibitors.
Previous work had suggested that ADS-J1, a polyanion with
potent anti-HIV activity, would interact with a highly
conserved hydrophobic cavity on the surface of the gp41
core when the gp41 fusion intermediate is formed (Chan et
al., 1997; Debnath et al., 1999). It was also shown that
ADS-J1 blocked the fusion of H9/HIV-1IIIB cells to MT-2
cells and the formation of N-36/C-34 complexes as well as
binding of antibodies to already formed complexes (Deb-
nath et al., 1999). Proof that negatively charged compounds
interact with gp41 would renew the scientific interest in the
mode of action of a family of compounds that have been
long known to block HIV replication.
As the previous coculture experiments performed with
ADS-J1 (Debnath et al., 1999) show the effect of the
compound on the multistep process of HIV entry, we were
interested in precisely defining its molecular target. The
observation that ADS-J1 was similarly active against wild-
type and C34- and T-20-resistant strains suggested different
mechanism of action than peptidic fusion inhibitors. ADS-
J1 anti-HIV activity against polyanion-resistant strains at
roughly the same concentrations needed to block wild-type
virus replication indicated either an increased potency over
other polyanions, a different binding site in the gp120 or
alternatively an interaction with gp41 as previously sug-
gested. The latest being further supported by our observa-
tion that AR177-resistant virus was sensitive to ADS-J1 but
its binding to lymphoid cells could not be blocked by ADS-
J1. Conversely, wild-type NL4-3 virus binding and repli-
cation were sensitive to ADS-J1.
Selection of virus resistance to ADS-J1 allows to propose
an explanation for the mechanism of action of this
compound. We chose the AR177-resistant virus for develop-
ment of resistance as our experiments suggested that gp120
binding of this virus would not be affected by the presence
of the ADS-J1. Thus, the requirement of mutations in gp120
needed to overcome the inhibitory activity of virus–cell
binding would be bypassed by AR177 resistance.
Mutations that confer resistance to AR177 slightly
increased (up to 4-fold) the EC50 for ADS-J1. However,
further passage in the presence of ADS-J1 was required to
generate a stronger reduction in sensitivity (up to 9-fold
with respect to the AR177-resistant NL4-3) that never-
theless remained weak if compared to the development of
resistance to C34 (1250-fold in a similar time span). These
results highlight the costs for HIV to mutate into a
polyanion-resistant virus that has often required a large
number of passages (Menendez-Arias and Este, 2004) and
may lead to loss of viral fitness (Armand-Ugon et al.,
2003b; Pollakis et al., 2001). The observation that resistance
to DS is lost in the absence of selective pressure and the
reversion of the K322Q mutation suggest that polyanionresistance has indeed a fitness cost to the virus. However,
when cultured in presence of ADS-J1, selective pressure
over the K322 residue is maintained and the K322E
mutation preserved. C34 passage of the AR177-resistant
virus generates a single mutation in gp41.
Together with the concomitant emergence of mutations
in gp120 further to those already present in the AR177-
resistant virus, our results point to gp120 as the site of
interaction of ADS-J1 with HIV. Besides the K490R
mutation, the mutations common to all four ADS-J1-
resistant viruses were located in the V3 loop (K322E,
N325D and R327T), a putative site of interaction with
active anti-HIV polyanions (Batinic and Robey, 1992).
However, the interaction of polyanions with other sites of
gp120 is not excluded, explaining the requirement of
mutations in gp120 regions outside of the V3 loop. The
flexibility of the gp120 glycoprotein permits the presenta-
tion of two different structures, when ligated and unligated
to the CD4 receptor (Chen et al., 2005), and affinity of
heparan sulfate (HS) for gp120 is affected by these
conformational changes (Vives et al., 2005). When CD4-
induced, gp120 conforms a highly HS affinity site in which
V3 is a forming part. The appearance of mutations in the
resistant viruses mainly in V3 but also in some in the V2
suggests that ADS-J1 can interact with the more exposed
CD4-induced-shaped site (Vives et al., 2005). The observa-
tion that addition of ADS-J1 may be delayed to a time
similar to that of a CXCR4 inhibitor further supports the
hypothesis that selected polyanions may bind to the gp120
coreceptor binding site as an alternative mechanism of
action to their effect on virus–cell binding. Furthermore, a
dramatic change in net charge as consequence of ADS-J1
resistance confirms previous models that propose a basic
face of gp120 that includes but it is not constrained to the
V3 loop of X4 HIV strains (Moulard et al., 2000).
Preliminary computer calculations suggest that ADS-J1
interacts with positively charged regions and the coreceptor
binding site of gp120 (data not shown), confirming our
experimental data. Our results suggest the possibility that
further passage with ADS-J1 may induce a reduction in the
net charge of the V3 loop that could lead to a coreceptor
switch from CXCR4 to CCR5, in particular with HIV
strains that are less positively charged than the NL4-3 strain
used herein. Polyanion resistance significantly alters HIV
binding affinity (Bobardt et al., 2004) (Fig. 1) and possibly
the electrostatic interactions that are required for association
of gp120 with coreceptors.
HIV fusion inhibitors represent an important class of
agents for the treatment of advanced HIV patients (Lalezari
et al., 2003; Lazzarin et al., 2003). Preventing gp41-
dependent fusion blocks HIV replication and the pathogenic
effects induced by HIV envelope on uninfected cells
(Barretina et al., 2003; Blanco et al., 2003, 2004), under-
scoring the need for agents that effectively target HIV
fusion. New efforts on the development of drug-like fusion
inhibitors have pointed to small molecules shown to
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C34 peptide mixtures (Jiang et al., 2004). Further analysis
of these active compounds should be performed in order to
more precisely define the molecular target in the viral entry
process.Materials and methods
Cell lines, viruses and compound
The lymphoid cell line MT-4 was obtained through the
MRC AIDS Reagent Program. The human T-lymphoblas-
toid A3.01/CCR5-A5 and F7 (CEM-CCR5) cell lines were
obtained from the NIH AIDS Research and Reference
Program. Cells were grown in RPMI 1640 supplemented
with 10% fetal calf serum and antibiotics as described
before (Barretina et al., 2004).
The HIV-1 BaL strain and the original HIV-1 NL4-3
strain were obtained from the Medical Research Council
AIDS reagent program. The HIV-1 NL4-3 strain that are
resistant to AR177, dextran sulfate (DS) and C34 have been
described elsewhere (Armand-Ugon et al., 2003a; Este et
al., 1997, 1998; Menendez-Arias and Este, 2004).
ADS-J1 was provided by S. Jiang, Lindsley F. Kimball
Research Institute, New York. 3-Azido-3-deoxythymidine
(AZT) and dextran sulfate (DS) were purchased from
Sigma-Aldrich (Madrid, Spain), zintevir (AR177),
AMD3100 and C34 were synthesized as described else-
where (Armand-Ugon et al., 2003a; Donzella et al., 1998;
Ojwang et al., 1995a). Saquinavir (SQV) was kindly
provided by the NIH AIDS Reference Reagent Program.
Efuvirtide (Fuzeon, T-20) (Barretina et al., 2004; Kilby et
al., 1998) was synthesized by the Peptide Synthesis Service
of Universitat de Barcelona.
Antiviral activity evaluations
HIV-1 strains were titered in MT-4 cells after acute
infection, and infectivity was measured by evaluating the
cytopathic effect induced after 5-day cultures as described
(Armand-Ugon et al., 2003a). Anti-HIV activity and
cytotoxicity measurements in MT-4 cells were based on
viability of cells that had been infected or not infected with
HIV-1, all exposed to various concentrations of the test
compound. After the MT-4 cells were allowed to proliferate
for 5 days, the number of viable cells was quantified by a
tetrazolium-based colorimetric method (MTT method) as
described (Armand-Ugon et al., 2003a).
Binding assay
5.0  105 MT-4 cells were exposed in 24-well plates and
in a 1 ml final volume to a multiplicity of infection (MOI) of
0.9 of wild-type NL4-3, NL4-3 resistant to AR177 and
cross-resistant to DS. When indicated, incubations wereperformed with AZT (1 Ag/ml), AR177 (50 Ag/ml) or ADS-
J1 (50 Ag/ml). After 1-h incubation at 4 -C, cells were
washed three times with 1 phosphate-buffered saline
(PBS), and HIV-1 p24 antigen bound to the cell pellet
was quantified with the INNOTEST HIV Ag mAb ELISA
kit (Innogenetics, Barcelona, Spain).
Development of resistant HIV-1
1  105 MT-4 cells were incubated with the NL4-3/
AR177-resistant HIV-1 strain (MOI 0.003) in 48-well plates
in a final 0.7 ml volume of growth medium. Passages were
started with an ADS-J1 concentration of 0.5-, 1-, 2.5- and 5-
fold, the EC50 previously determined (i.e., 0.7 Ag/ml, 1.5
Ag/ml, 3.7 Ag/ml and 7.5 Ag/ml, respectively). When
extensive cytopathic effect (CPE) was observed, cultures
were centrifuged in a microcentrifuge (2 min, 3000 rpm),
and supernatants were used to infect fresh MT-4 cells. The
ADS-J1 concentration was progressively raised up to 20 Ag/
ml. For proceeding with further analysis of ADS-J1-cultured
viruses, the supernatants obtained from the last passage
were used to generate viral stocks in ADS-J1-free medium.
For C34 resistance development, we used the same method,
starting with 0.01 Ag/ml of peptide and finishing passages
when infected cultures reached 10 Ag/ml.
Sequence analysis of wild-type and drug-resistant strains
MT-4 cell pellets obtained from each stock were used for
the analysis of the proviral sequence. Genomic DNA was
extracted with the QIAamp DNA Blood Mini kit (Qiagen,
Hilden, Germany), and the env gene (from 5514 to 8910,
nucleotide position relative to HXB2) was amplified with
primers 5V-GATAAAGCCACCTTTGCCTAGT-3V and 5V-
TTCTAGGTCTCGAGATACTG-3V using the Expand High
Fidelity PCR System (Roche, Barcelona, Spain). Both
strands were amplified with the dRhodamine Terminator
Cycle Sequencing Ready Reaction kit (PE Biosystems,
Warringtong, England), and sequences from gp120 and
gp41 were collected by an ABI Prism 377 Genetic Analyzer,
and sequences were aligned and analyzed with the Sequence
Navigator v.1.0.1 program (PE Biosystems). Net charge of
the V3 variable loop at pH 7.0 was determined using the
GeneWorks 2.5.1 software.
Time of drug addition studies
MT-4 cells were infected with HIV-1 NL4-3 at a multi-
plicity of infection of 0.5 and incubated for 1 h at 20 -C in
the presence or absence of test compounds. Cells were then
washed twice in cool PBS and seeded in 96-well plates at a
concentration of 2  105 cells/well (final volume of 200 Al)
at a temperature of 37 -C. ADS-J1, dextran sulfate, AR177,
AMD3100, T-20, C34 or AZT were added at various times
postinfection or cultured in the absence of drug. Test
compounds were added at concentrations that completely
M. Armand-Ugo´n et al. / Virology 343 (2005) 141–149148block HIV replication (roughly 100-fold higher than the
determined EC50) of each drug in the standard assay
performed with MT-4 cells. Virus production was measured
by p24 antigen determination in the cell supernatant after
30 h postinfection with a commercial p24 antigen ELISA
(Innogenetics, Barcelona, Spain).Acknowledgments
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